Systematic review and meta-analysis shows worse liver transplant survival for Black patients compared to White patients
Black patients faced worse survival rates after liver transplant compared to White patients in this review
This systematic review and meta-analysis evaluated overall patient and graft survival after liver transplant across diverse ethnic populatio…
A large review of twelve studies found Black patients had lower survival rates after liver transplants than White patients. Asian and Hispan…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC
New Drug Combo Outperforms Standard Care for Liver Cancer
This meta-analysis evaluated PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in treatment-naive individuals with advanced hepatocellu…
A powerful two-drug combination cuts the risk of death by 35 percent compared to the standard treatment for people with advanced liver cance…
Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
A Hidden Protein Switch May Fuel Cancer Growth and Drug Resistance
This narrative review addresses multiple malignancies including hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pa…
A single protein called PRMT3 helps multiple cancers grow, hide from the immune system, and resist chemotherapy, making it a promising new t…
Preoperative indicators predict microvascular invasion in hepatocellular carcinoma patients
New Model Predicts Liver Cancer Spread Before Surgery
This meta-analysis evaluated preoperative indicators including alpha-fetoprotein, tumor size, and tumor margin to predict microvascular inva…
A simple scoring tool now predicts if liver cancer has spread into tiny blood vessels, helping surgeons plan safer operations and improve su…
Surgical resection shows superior survival outcomes compared to radiofrequency ablation for small hepatocellular carcinoma cases
Surgery offers better long-term survival and lower recurrence rates for small liver cancer cases compared to ablation
A meta-analysis of 3,551 patients indicates surgical resection offers significantly better long-term survival than radiofrequency ablation f…
A review of 3,551 patients found surgery works better than ablation for small liver tumors. People who had surgery lived longer and had fewe…
Metabolic dysfunction-associated steatotic liver disease patients with advanced fibrosis face high hepatocellular carcinoma risk over ten years
Liver cancer risk much higher with this common condition
A massive meta-analysis of nearly four million individuals reveals stark differences in hepatocellular carcinoma development based on fibros…
Many people with fatty liver disease never know their risk of liver cancer could be rising, especially if they have undetected scarring.
Meta-analysis identifies genetic variants linked to HBV susceptibility and HCC risk
Genetic Keys Unlock Why Some Get Liver Cancer From Hepatitis B
This meta-analysis of East Asian cohorts examined genetic variants associated with hepatitis B virus infection and hepatocellular carcinoma …
New research shows specific gene changes help explain why some people get Hepatitis B while others stay healthy.
Meta-analysis finds R1 vascular margin acceptable for HCC but not CLM in minimally invasive liver surgery
Tumor margin choice matters differently for liver cancer types
This meta-analysis of 839 patients undergoing minimally invasive liver surgery found that R1 vascular margin (R1v) hepatectomy yields local …
For liver cancer, leaving a narrow margin is safe. For colorectal metastases, it raises recurrence risk.
Combination TACE plus systemic therapy showed no PFS benefit but improved OS in BCLC-C HCC patients compared to TACE alone
Combination therapy improves survival for advanced liver cancer patients in one study
This retrospective cohort study evaluated 142 patients with intermediate or advanced-stage hepatocellular carcinoma at Hunan Provincial Peop…
Combination therapy may extend life for advanced liver cancer patients, but results vary by disease stage and need more research.
Ultrasound-based radiomics nomogram predicts p53 expression in 172 patients with hepatocellular carcinoma
New Ultrasound Tool Predicts Liver Cancer Gene Status Accurately
This cohort study evaluated an ultrasound-based radiomics nomogram integrating variational autoencoder-derived deep features to predict p53 …
A new computer model can read liver ultrasound scans to predict a specific cancer gene mutation that helps guide treatment plans for patient…
Randomized Phase II Trial Evaluates Ociperlimab Plus Tislelizumab and BAT1706 in Advanced Hepatocellular Carcinoma
Adding a new drug did not help liver cancer patients survive longer
This randomized phase II trial enrolled 94 patients with advanced hepatocellular carcinoma.
A new drug combination showed promise for advanced liver cancer, but adding a third drug did not improve results.
Questions about Hepatocellular Carcinoma
Are there differences in how hepatocellular carcinoma develops based on my liver fibrosis stage?
Yes, advanced liver fibrosis (stage F3-F4) significantly increases the risk of developing hepatocellular carcinoma compared to no or mild fibrosis, with higher cumulative incidence over time.
Full answer →What gaps exist between lab findings and real-world treatment for hepatocellular carcinoma?
Lab findings often don't translate to real-world HCC care due to tumor heterogeneity, racial disparities, and lack of validated biomarkers for routine use.
Full answer →Do Black patients have worse survival rates after a liver transplant for hepatocellular carcinoma?
Yes, Black patients have worse survival after liver transplant for hepatocellular carcinoma, with a 27% higher risk of death compared to White patients.
Full answer →Does having advanced liver scarring increase my risk of developing hepatocellular carcinoma?
Yes, advanced liver scarring (fibrosis/cirrhosis) significantly raises your risk of developing hepatocellular carcinoma, especially in MASLD patients.
Full answer →